SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

INmune Bio Inc. (INMB) News

Follow INmune Bio Inc. (INMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol INMB Asset equity Sector Markets 90 days 9 Last 0.8232 Updated Nov 05, 2026, 10:05 PM UTC Open live news feed Open INMB chart & news
L INmune Bio Reports Results for Quarter Ended September 30 The wire headline reports quarterly results; the supplied body contains no financial figures. EARNINGS | Nov 05, 2026, 10:05 PM UTC M INmune Bio to Report Third-Quarter Financial Results EQUITY | Oct 29, 2026, 01:19 PM UTC M INmune Bio Prices $4.50 Million Registered Direct Offering and Private Placement INmune Bio announced pricing of a $4.50 million registered direct offering and concurrent private placement. EQUITY | Oct 28, 2026, 12:08 PM UTC M Inmune Bio Signs Uniphar Deal and Submits UK Pre-MAA for Ebstrocel Inmune Bio announced a Master Services Agreement with Uniphar to support international access for Ebstrocel and submitted a final pre-MAA to the UK MHRA. EQUITY | Oct 21, 2026, 01:03 PM UTC H Full Transcript: INmune Bio Q2 2026 Earnings Call INmune Bio (NASDAQ: INMB ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visi LIVE | Oct 12, 2026, 09:54 AM UTC L Inmune Bio adds R. Duane Clark II and James Sapirstein to board Inmune Bio appointed R. Duane Clark II and James Sapirstein to its Board of Directors and named both to the Nominating and Corporate Governance Committee.Original SEC Filing: Inmune Bio, Inc. [ INMB ] - 8-K - Sep. 14, 20 REGULATION | Sep 14, 2026, 08:13 PM UTC L INmune Bio to present at H.C. Wainwright Global Investment Conference INmune Bio said its on-demand presentation will be available September 11, 2026, at 7:00 A.M. (ET). EQUITY | Sep 09, 2026, 12:03 PM UTC L INMB - INmune Bio to Present at the H.C. Wainwright Global Investment Conference INMB - INmune Bio to Present at the H.C. Wainwright Global Investment Conference EQUITY | Sep 09, 2026, 12:01 PM UTC L INmune Bio advances Ebstrocel toward EMA marketing authorization INmune Bio says it has advanced Ebstrocel toward European marketing authorization via EMA regulatory filings, per TradeXchange Newsdesk. EQUITY | Aug 26, 2026, 11:00 AM UTC M INmune Bio Receives $4.6M R&D Rebates INmune Bio gets $4.6M R&D rebates EQUITY | Jul 31, 2026, 11:00 AM UTC L INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th - Click For Rele INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th EARNINGS | Jul 31, 2026, 11:00 AM UTC M INMB Establishes Scientific Advisory Board INMB forms advisory board for CORDStrom platform EQUITY | Jul 30, 2026, 11:00 AM UTC L INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study Inmune Bio - xpro1595 selectively neutralizes soluble tnf - Cordstrom to file m EQUITY | Jul 15, 2026, 11:02 AM UTC L INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has offici EQUITY | Jul 01, 2026, 11:07 AM UTC H INMB: UK Approves PIP The UK Medicines & Healthcare Products Regulatory Agency approves the Pediatric Investigation Plan for INmune Bio's Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa EQUITY | Jun 25, 2026, 11:13 AM UTC M INMB Gets MHRA Approval INmune Bio Inc. achieves MHRA approval of PIP for CORDStrom EQUITY | Jun 25, 2026, 11:00 AM UTC M INMB Receives MHRA Alignment INmune Bio receives MHRA written alignment supporting planned 2026 UK conditional marketing authorization application for CORDStrom in RDEB EQUITY | Jun 23, 2026, 12:02 PM UTC